InSilico Medicine Cayman TopCo (HKG:3696)

Market Cap	26.12B
Revenue (ttm)	420.77M
Net Income (ttm)	-348.07M
Shares Out	555.76M
EPS (ttm)	-4.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,128,798
Average Volume	9,088,701
Open	45.10
Previous Close	44.90
Day's Range	43.50 - 48.46
52-Week Range	29.98 - 48.46
Beta	n/a
RSI	n/a
Earnings Date	n/a

About HKG:3696

InSilico Medicine Cayman TopCo operates as an artificial intelligence (AI)-based biotech company that helps to develop and manufacture novel drugs in Hong Kong, the United States, the United Kingdom, Mainland China, and internationally. The company develops solutions to discover and develop drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. It also offers Pharma.AI platform, a commercially end-to-end generative Al software and automation platform which is ...

• Industry: Software - Infrastructure
• Sector: Technology
• Founded: 2014
• Employees: 319
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3696

Financial Performance

In 2024, HKG:3696's revenue was $85.83 million, an increase of 67.71% compared to the previous year's $51.18 million. Losses were -$17.10 million, -91.92% less than in 2023.

Financial numbers in USD